The Varieties of the Psychedelic Experience: A Preliminary Study of the Association Between the Reported Subjective Effects and the Binding Affinity Profiles of Substituted Phenethylamines and Tryptamines
This data-analytic study compared the similarity between several different psychedelic compounds, in terms of their reported subjective effects, binding affinity profiles, and molecular structures. Through the application of a novel machine-learning algorithm to the experience reports sampled from Erowid, the authors found that differences in subjective experience could be predicted by target binding site affinity and/or their conformational receptor states of the respective molecules. Notabely, the 5-HT receptor subtypes yielded relatively poor predictions by themself in contrast to dopamine receptors (D1-5), which highlights that the dopaminergic action of LSD (in contrast to psilocybin) may elicit different types of subjective experiences.
Authors
- Enzo Tagliazucchi
- Claudio Pallavicini
- Federico Zamberlan
Published
Abstract
Introduction
Classic psychedelics are substances of paramount cultural and neuroscientific importance. A distinctive feature of psychedelic drugs is the wide range of potential subjective effects they can elicit, known to be deeply influenced by the internal state of the user (“set”) and the surroundings (“setting”). The observation of cross-tolerance and a series of empirical studies in humans and animal models support agonism at the serotonin (5-HT)2A receptor as a common mechanism for the action of psychedelics. The diversity of subjective effects elicited by different compounds has been attributed to the variables of “set” and “setting,” to the binding affinities for other 5-HT receptor subtypes, and to the heterogeneity of transduction pathways initiated by conformational receptor states as they interact with different ligands (“functional selectivity”). Here we investigate the complementary (i.e., not mutually exclusive) possibility that such variety is also related to the binding affinity for a range of neurotransmitters and monoamine transporters including (but not limited to) 5-HT receptors.
Methods
Building on two independent binding affinity datasets (compared to “in silico” estimates) in combination with natural language processing tools applied to a large repository of reports of psychedelic experiences (Erowid’s Experience Vaults), ...
Results
... we obtained preliminary evidence supporting that the similarity between the binding affinity profiles of psychoactive substituted phenethylamines and tryptamines is correlated with the semantic similarity of the associated reports. We also showed that the highest correlation was achieved by considering the combined binding affinity for the 5-HT, dopamine (DA), glutamate, muscarinic and opioid receptors and for the Ca+ channel. Applying dimensionality reduction techniques to the reports, we linked the compounds, receptors, transporters and the Ca+ channel to distinct fingerprints of the reported subjective effects. To the extent that the existing binding affinity data is based on a low number of displacement curves that requires further replication, our analysis produced preliminary evidence consistent with the involvement of different binding sites in the reported subjective effects elicited by psychedelics.
Discussion
Beyond the study of this particular class of drugs, we provide a methodological framework to explore the relationship between the binding affinity profiles and the reported subjective effects of other psychoactive compounds.
Research Summary of 'The Varieties of the Psychedelic Experience: A Preliminary Study of the Association Between the Reported Subjective Effects and the Binding Affinity Profiles of Substituted Phenethylamines and Tryptamines'
Introduction
Classic psychedelics produce a wide range of subjective effects that depend strongly on set and setting but are also thought to share a common mechanism via partial agonism at serotonin (5-HT) 2A receptors. Despite this commonality, users and some experimental work report phenomenological differences across compounds, including among substituted phenethylamines and tryptamines. Previous explanations for that diversity emphasise set/setting, functional selectivity at 5-HT receptors, or differing affinities for other 5-HT subtypes; Zamberlan and colleagues investigate a complementary possibility that polypharmacology beyond the 5-HT system—including affinities at other neurotransmitter receptors, transporters and ion channels—contributes to the variety of reported subjective effects. This study aims to test whether similarity in binding affinity profiles across a range of targets is associated with similarity in the language used to describe subjective experiences. Using binding affinity data from two independent sources and natural language processing applied to a large repository of self‑reported psychedelic experience narratives, the investigators ask whether compounds with similar affinity “fingerprints” have semantically similar reports, and whether particular receptors or receptor combinations better predict the reported phenomenology. The work is presented as a methodological framework that could be applied to other psychoactive compounds as binding and report data accumulate.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Create a free account to open full-text PDFs.
Study Details
- Study Typemeta
- Journal
- Compounds
- Topics
- Authors
- APA Citation
Zamberlan, F., Sanz, C., Martínez Vivot, R., Pallavicini, C., Erowid, F., Erowid, E., & Tagliazucchi, E. (2018). The Varieties of the Psychedelic Experience: A Preliminary Study of the Association Between the Reported Subjective Effects and the Binding Affinity Profiles of Substituted Phenethylamines and Tryptamines. Frontiers in Integrative Neuroscience, 12. https://doi.org/10.3389/fnint.2018.00054
References (32)
Papers cited by this study that are also in Blossom
Bowdle, A. T., Radant, A. D., Cowley, D. S. et al. · Anesthesiology (1998)
Carbonaro, T. M., Eshleman, A. J., Forster, M. J. et al. · Psychopharmacology (2014)
Carhart-Harris, R. L., Leech, R., Shanahan, M. et al. · Frontiers in Human Neuroscience (2014)
Dos Santos, R. G., Osório, F. L., Crippa, J. A. et al. · Neuroscience and Biobehavioral Reviews (2016)
Gonza ´lez-Maeso, J., Weisstaub, N. V., Zhou, M. et al. · Neuron (2007)
Hanks, J. B., González-Maeso, J. · ACS Chemical Neuroscience (2012)
Kometer, M., Vollenweider, F. X. · Behavioral Neurobiology of Psychedelic Drugs (2016)
Sumiyoshi, T., Kraehenmann, R., Pokorny, D. et al. · Frontiers in Pharmacology (2017)
Kraehenmann, R. ;., Pokorny, D. ;., Vollenweider, L. ;. et al. · Psychopharmacology (2017)
López-Giménez, J. F., González-Maeso, J. · Current Topics in Behavioral Neurosciences (2017)
Show all 32 referencesShow fewer
Moya, P. R., Berg, K. A., Gutiérrez-Hernandez, M. A. et al. · Journal of Pharmacology and Experimental Therapeutics (2007)
Nichols, D. E. · Journal of Psychoactive Drugs (1986)
Nichols, D. E. · Pharmacological Reviews (2016)
Nichols, D. E. · Current Topics in Behavioral Neurosciences (2017)
King, C., Nichols, D. E. · Nature Reviews Neuroscience (2013)
Preller, K. H., Herdener, M., Pokorny, T. et al. · Current Biology (2017)
Preller, K. H., Vollenweider, F. X. · Behavioral Neurobiology of Psychedelic Drugs (2016)
Quednow, B. B., Kometer, M., Geyer, M. A. et al. · Neuropsychopharmacology (2011)
Ray, T. S. · PLOS ONE (2010)
Rickli, A., Luethi, D., Reinisch, J. et al. · Neuropharmacology (2015)
Rickli, A., Moning, O. D., Hoener, M. C. et al. · European Neuropsychopharmacology (2016)
Sanz, C., Zamberlan, F., Erowid, E. et al. · Frontiers in Neuroscience (2018)
Schartner, M., Carhart-Harris, R. L., Barrett, A. B. et al. · Scientific Reports (2017)
Schenberg, E. E., de Castro Comis, M. A., Alexandre, J. F. M. et al. · Journal of Psychedelic Studies (2017)
Schenberg, E. E., de Castro Comis, M. A., Chaves, T. V. et al. · Journal of Psychopharmacology (2014)
Studerus, E., Gamma, A., Kometer, M. et al. · PLOS ONE (2012)
Studerus, E., Gamma, A., Vollenweider, F. X. · PLOS ONE (2010)
Sweetnam, P. M., Lancaster, J., Snowman, A. et al. · Psychopharmacology (1995)
Van Amsterdam, J., Opperhuizen, A., Van Den Brink, W. · Regulatory Toxicology and Pharmacology (2011)
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A. et al. · NeuroReport (1998)
Wacker, D., Wang, S., Mccorvy, J. D. et al. · Cell (2017)
Winter, J. C. · Psychopharmacology (2008)
Cited By (19)
Papers in Blossom that reference this study
Schlomberg, J. T. T., Meling, D., Grylka, R. et al. · Scientific Reports (2026)
Piccinini, J. I., Perl, Y. S., Pallavicini, C. et al. · Communications Biology (2025)
Shinozuka, K., Jerotic, K., Mediano, P. A. M. et al. · Translational Psychiatry (2024)
McAlpine, R., Kamboj, S. K. · Scientific Reports (2024)
Mallaroni, P., Mason, N. L., Reckweg, J. T. et al. · Clinical Pharmacology and Therapeutics (2023)
Wießner, I., Falchi, M., Daldegan-Bueno, D. et al. · European Neuropsychopharmacology (2023)
Forstmann, M., Kettner, H. S., Sagioglou, C. et al. · Journal of Psychopharmacology (2023)
Aqil, M., Roseman, L. · Neuropharmacology (2022)
Swee, M. B., Nayak, S., Hurwitz, E. et al. · PLOS ONE (2022)
Sanz, C., Cavanna, F., Muller, S. et al. · Psychopharmacology (2022)
Show all 19 papersShow fewer
Friedman, S. F., Ballentine, G. · Biorxiv (2022)
Tagliazucchi, E. · Frontiers in Pharmacology (2022)
Basedow, L. A., Riemer, T. G., Reiche, S. et al. · Frontiers in Pharmacology (2021)
Hirschfeld, T., Smit-Rigter, L., Van Der Gouwe, D. et al. · Current Addiction Reports (2021)
Ballentine, G., Friedman, S. F., Bzdok, D. · Science Advances (2021)
Cox, D. J., Garcia-Romeu, A., Johnson, M. W. · The American Journal of Drug and Alcohol Abuse (2021)
Pallavicini, C., Cavanna, F., Zamberlan, F. et al. · Journal of Psychopharmacology (2021)
Sanz, C., Pallavicini, C., Carrillo, F. et al. · Consciousness and Cognition (2021)
Pallavicini, C., Vilas, M. G., Villarreal, M. et al. · NeuroImage (2019)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.